Exai Bio

Exai Bio is a privately held, next-generation liquid biopsy company headquartered in Palo Alto, California, in the United States. The company is developing an RNA-based platform that combines novel biomarkers with artificial intelligence to deliver actionable insight into cancer biology from a simple blood draw. Its stated mission is to enable a world where cancer can be detected early, diagnosed accurately, managed precisely, and ultimately cured. The scientific foundation of Exai Bio is its proprietary oncRNA technology, which originated in the laboratories of the University of California, San Francisco. There, Dr. Hani Goodarzi and Dr. Lisa Fish discovered the potential of identifying cancer-specific oncRNAs, finding signals in what appeared to others as noise. With these biomarkers and AI, the company aims to connect the dots and uncover clinical insights that were not previously possible. Exai describes itself as a team of "exonauts" — intrepid leaders in RNA biology, liquid biopsy, and artificial intelligence drawn from academic and industry backgrounds including UCSF, Stanford University, MIT, the Karolinska Institute, the University of Waterloo, Rockefeller University, Princeton University, Johns Hopkins University, UCLA, UC Berkeley, as well as companies such as Bluestar Genomics, Illumina, Guardant Health, Myriad Genetics, Google, 23andMe, Deep Genomics, and Exact Sciences. Exai Bio positions itself at the intersection of RNA science and machine learning, with a focus on early cancer detection. Its leadership includes Michael Nall as President and Chief Operating Officer, Hani Goodarzi as Chief Technology Officer, Lee Schwartzberg as Chief Medical Officer, Carolyn Wang as Vice President of People and Culture, and Seema Singh Bhan leading Public Policy and External Affairs. Babak Alipanahi is Founder and Chief Scientific Officer. The company also draws on a scientific and medical advisory network that includes former U.S. Secretary of Veterans Affairs David Shulkin, former Jefferson Health CEO Stephen Klasko, and academic researchers from institutions such as UCSF, UPMC, Duke University, Stanford University, Cornell University, and the Englander Institute for Precision Medicine. As a private company, Exai Bio does not disclose a stock ticker or public listing. Its commercial focus is on the United States market, where it is developing blood-based tests intended to change the future of early cancer detection by providing clinical insights into cancer biology. The company maintains an active research and hiring presence and presents its platform as a potential foundation for how cancer is diagnosed, treated, and managed.

Exai Bio's story begins in the laboratories of the University of California, San Francisco, where Dr. Hani Goodarzi and Dr. Lisa Fish discovered the potential of identifying cancer-specific oncRNAs. By looking where others in the field had not, they found new biomarkers that the company says will pave the way to changing the future of diagnostics. This oncRNA technology became the scientific foundation on which Exai Bio was built. The company describes its formation as building a new venture from the ground up, a process that "really takes a village." Dr. Hani Goodarzi is credited as Founder and Scientific Advisor, and Babak Alipanahi is identified as Founder and Chief Scientific Officer. Exai Bio brought together leaders in RNA biology, liquid biopsy, and artificial intelligence, drawing on academic and industry experience from institutions including UCSF, Stanford University, MIT, the Karolinska Institute, the University of Waterloo, Rockefeller University, Princeton University, Johns Hopkins University, UCLA, and UC Berkeley, as well as companies such as Bluestar Genomics, Illumina, Guardant Health, Myriad Genetics, Google, 23andMe, Deep Genomics, and Exact Sciences. As the company grew, it positioned itself as a next-generation liquid biopsy company with a mission to enable a world where cancer can be detected early, diagnosed accurately, managed precisely, and ultimately cured. Its platform uses novel RNA biomarkers and AI to deliver actionable insight into cancer biology from a simple blood draw. Exai Bio has stated that it is now among the veterans in the field of RNA-based diagnostics. Looking ahead, Exai Bio plans to change the future of early cancer detection by providing clinical insights into cancer biology. The company maintains an active research and hiring presence and emphasizes that fulfilling its vision requires hard work, dedication, and collaboration. Its leadership team includes Michael Nall as President and Chief Operating Officer, Hani Goodarzi as Chief Technology Officer, Lee Schwartzberg as Chief Medical Officer, Carolyn Wang as Vice President of People and Culture, and Seema Singh Bhan leading Public Policy and External Affairs. A scientific and medical advisory network supports the company, including former U.S. Secretary of Veterans Affairs David Shulkin, former Jefferson Health CEO Stephen Klasko, and researchers from UCSF, UPMC, Duke University, Stanford University, Cornell University, and the Englander Institute for Precision Medicine.

• oncRNA technology discovered in the laboratories of the University of California, San Francisco by Dr. Hani Goodarzi and Dr. Lisa Fish.

• Exai Bio founded as a next-generation liquid biopsy company building on oncRNA technology.

• Company assembles leadership team and scientific advisory board spanning RNA biology, liquid biopsy, and artificial intelligence.

A next-generation liquid biopsy company combining novel RNA biomarkers and AI to enable early cancer detection from a blood draw.

• RNA-based liquid biopsy platform

  A next-generation platform that uses novel RNA biomarkers and AI to deliver actionable insight into cancer biology from a simple blood draw.

• oncRNA biomarkers

  Cancer-specific oncRNAs discovered by Dr. Hani Goodarzi and Dr. Lisa Fish at UCSF, forming the scientific basis of Exai Bio's diagnostics.

1. 1Exai Bio - RNA & AI Liquid Biopsy for Early Cancer Detectionexai.bio
2. 2Our History | Exaiexai.bio
3. 3Advisors | Exaiexai.bio
4. 4Leadership | Exaiexai.bio
5. 5Exai Bio (United States) - Wikidatawikidata.org